Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Jun 26;8(1):9713.
doi: 10.1038/s41598-018-27950-9.

Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes

Feng-Fei Li  1 , Bing-Li Liu  1 , Guo-Ping Yin  1 , Reng-Na Yan  1 , Dan-Feng Zhang  1 , Jin-Dan Wu  1 , Lei Ye  2 , Xiao-Fei Su  1 , Jian-Hua Ma  3
Affiliations
Randomized Controlled Trial

Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes

Feng-Fei Li et al. Sci Rep. .

Abstract

To investigate whether metformin add-on to the continuous subcutaneous insulin infusion (Met + CSII) therapy leads to a significant reduction in insulin doses required by type 2 diabetes (T2D) patients to maintain glycemic control, and an improvement in glycemic variation (GV) compared to CSII only therapy. We analyzed data from our two randomized, controlled open-label trials. Newly diagnoses T2D patients were randomized assigned to receive either CSII therapy or Met + CSII therapy for 4 weeks. Subjects were subjected to a 4-day continuous glucose monitoring (CGM) at the endpoint. Insulin doses and GV profiles were analyzed. The primary endpoint was differences in insulin doses and GV between the two groups. A total of 188 subjects were admitted as inpatients. Subjects in metformin add-on therapy required significantly lower total, basal and bolus insulin doses than those of control group. CGM data showed that patients in Met + CSII group exhibited significant reduction in the 24-hr mean amplitude of glycemic excursions (MAGE), the standard deviation, and the coefficient of variation compared to those of control group. Our data suggest that metformin add-on to CSII therapy leads to a significant reduction in insulin doses required by T2D patients to control glycemic variations.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
The hourly glucose concentrations in patients between the two groups,*compared with control Group (P < 0.05).
See this image and copyright information in PMC

References

    1. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes care. 1997;20:1353–1356. doi: 10.2337/diacare.20.9.1353. - DOI - PubMed
    1. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes care. 2004;27:1028–1032. doi: 10.2337/diacare.27.5.1028. - DOI - PubMed
    1. Retnakaran R, Drucker DJ. Intensive insulin therapy in newly diagnosed type 2 diabetes. Lancet. 2008;371:1725–1726. doi: 10.1016/S0140-6736(08)60736-9. - DOI - PubMed
    1. Li Y, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes care. 2004;27:2597–2602. doi: 10.2337/diacare.27.11.2597. - DOI - PubMed
    1. Chen A, et al. Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment. Diabetes care. 2012;35:474–481. doi: 10.2337/dc11-1638. - DOI - PMC - PubMed

Publication types